STING trial for high-risk neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of chemotherapy (temozolomide and irinotecan), natural killer cells (NK cells), and an antibody therapy (GD2 mAb) to see if it can help children and young adults with high-risk neuroblastoma that has not responded to treatment or has come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 and 31 years old.
- You have high-risk neuroblastoma that has come back, not responded, or is still present after treatment.
- You have active tumor that can be seen on a special scan (MIBG), biopsy, or in the bone marrow.
- Your organs (like bone marrow, kidneys, liver, heart, lungs) are working well enough.
- You must stop certain other treatments (like chemotherapy, radiation, or other trial drugs) for specific periods before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation (MIBG) with two medicines, vorinostat and dinutuximab, for children and young adults with high-risk neuroblastoma that has returned or not fully responded to earlier treatment. The goal is to see if adding these medicines helps the radiation work better and improves outcomes.
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
This trial tests a personalized treatment plan for children with high-risk neuroblastoma, a type of nerve tissue cancer. It aims to improve outcomes by tailoring therapy based on each child's tumor characteristics and response to prior treatment.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.